GPA pts can have dacryoadenitis (ddx 👇) where pt's lateral eye/s can be curved due to swelling. How to examine? Use thumb to retract eyelid & reveal lacrimal gland underneath, ask pt to look medially #ACR22 @RheumNow @rheumarhyme @doktora_ging @PhRheumaJr #RheumTwitter https://t.co/pJYMffhYWx

Deucravacitinib (TYK2 inihibitor) already studied in PsO and PsA, has show efficacy in a phase 2 trial for treatment of SLE. Improvement in SRI(4), BICLA, LLADS, CLASI-50 and joint count Abs#1117 @RheumNow #ACR22 https://t.co/XElIuMmud9

🦋Only 15% of pts with localized DLE develop SLE Risk factors for conversion: 🔸ANA+ at BL 🔸dsDNA+ 🔸Gen'd DLE 🔸Cytopenia 🔸Photosensitivity 🔸abn. UA #ACR22 @RheumNow @rheumarhyme https://t.co/n7cKjC1oaR

Tofighi et al. VTE in SLE nephritis. 10% VTE, 5.2% VTE after SLE nephritis diagnosis. Risks - Black patients, ds-DNA+, SDI, aPL+, SLEDAI. @RheumNow #ACR22 Abstr#0541 https://t.co/G6q0qvirf7 https://t.co/B8STBTMy14

• Prevalence of Venous Thrombo-Embolism in Lupus Nephritis and Associated Risk Fa…

Prelude to a Meeting #ACR22 https://t.co/ESjDnNue1H https://t.co/EHt5tgFOn3

• https://bit.ly/3EoPrRv

ACR Best Abstracts - Day 1 The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest). https://t.co/ndSBqYszlo https://t.co/vOHtLTFux6

• https://bit.ly/3EqlsZA

Across 9 trials of Upadacitinib in RA, PsA and AS, 40%–50% of patients had ≥ 2 CV risk factors, ≥ 65 years 6%–23%. Rates of adjudicated MACE and VTE with UPA were infrequent, consistent with background rates in RA, PsA, and AS Abst 0510 https://t.co/HDkQ6ELnAy #ACR22 @RheumNow https://t.co/SRJYdFFNIQ

• MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthriti…

New concept of sJIA to MAS as a continuum on the spectrum of disease severity. Molecular basis via impact of mTORC1 (mechanistic target of rapamycin complex 1) inhibition in Il1rn-/- mice. Looking forward to the full paper. Huang Z Abs004 https://t.co/3OtIp90PnG #ACR22 @RheumNow https://t.co/PPHQj8bYKu

• mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activati…

How can we differentiate statin-assoc autoimmune necrotizing myopathy from toxic statin #myopathy?🔎 Remember this important slide👇 #ACR22 @Rheumnow #acrreview https://t.co/hKMJuGDJWt

Statin therapy may exacerbate underlying neuromuscular disorders. ‼️REMEMBER☝️The only ABSOLUTE contraindication to statins are pts who are HMGCR+ #ACR22 @RheumNow #acrreview https://t.co/A3XGHlrm0X

Interesting study by Dr Ai Li Yeo and colleagues on repetitive anti-dsDNA testing and flare prediction: 🔅Fluctuations (⬆️and ⬇️) in anti-dsDNA >2 fold was assoc'd w/⬆️flares in all groups including persistently + pts. #ACR22 @RheumNow ABST#327 https://t.co/q0WXnIwV4A